You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Guidelines & Advice
About Guidelines Email Guidelines Team

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer

Version: 2 ID: GL 1-22-A Jul 2022
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
Sukhbinder Dhesy-Thind, Glenn G Fletcher, Phillip S Blanchette, Mark J Clemons, Sonal Gandhi, Rasna Gupta, Mihaela Mates, Ted Vandenberg


Guideline Objective

To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuvant therapy for patients with breast cancer.

Patient Population

Patients with early or locally advanced (non-metastatic) breast cancer

Intended Guideline Users

Medical oncologists and other clinicians involved in post-surgical (adjuvant) treatment of patients with breast cancer

Research Questions

  1. Does administration of bisphosphonates or other bone-modifying agents as adjuvant treatment in patients with breast cancer reduce metastasis and/or recurrence and improve survival?
  2. Does effectiveness depend on patient or disease characteristics, especially age or menopausal status (natural or induced menopause)?
  3. Do effectiveness and adverse effects differ according to which bisphosphonate or bone-modifying agent is used?
  4. What doses, duration of administration, and route (intravenous, oral) are optimal?
pdf download Summary (PDF) (233.68 KB)
pdf download Full Report (PDF) (1.36 MB)